Simon Williams

Dr. Williams has over 20 years of experience in creating, organizing, developing, licensing, financing, and managing new medical and chemical technologies from early-stage research through to commercially viable products. Prior to Akeso Biomedical, Dr. Williams was the President of Tepha, Inc., where he formulated a product development strategy for a new absorbable biomaterials technology that led to FDA regulatory clearance of 17 novel medical device products over 5 years. Products developed by Tepha included CR Bard’s Phasix™ hernia repair mesh, B. Braun Surgical’s MonoMax® absorbable sutures, Tornier’s Phantom Fiber™ for ligament and tendon repair, and Galatea’s GalaFLEX® mesh for plastic and reconstructive surgery. Dr. Williams is a co-founder of the bioscience company, Metabolix (NASDAQ: MBLX), and served on the Metabolix Board of Directors from its formation in 1992 until 2006. Dr. Williams was a lecturer in organic chemistry at Manchester University in England, a visiting scientist and NATO postdoctoral fellow at M.I.T., and completed a Ph.D. in organic chemistry at Cambridge University, England. Dr. Williams is a Fellow of the Royal Society of Medicine.